Safety and Efficacy of tPBM for Epileptiform Activity in Autism

2期 已完成 NCT06352372

摘要

For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children with abnormal EEGs with epileptiform discharges or with epilepsy. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical practice of treating autism. At the beginning, at five weeks, and at the end of study, the clinician will complete the CARS-2, SRS, CGI, and a caregiver interview; additionally, questionnaires will be administered to caregivers during one of the 1-hour weekly treatment sessions.

Childhood Autism Rating Scores (CARS)

Baseline, Week 5, Week 11 and Week 15 (One Month Follow-Up) · units on the CARS scale

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
• Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
• Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
• A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
• Maintenance TMS in Treatment Resistant Depression — Austin Messner
• Staccato Alprazolam and Photoparoxysmal Response — Nova Pneuma Inc.

全部试验